内科理论与实践 ›› 2022, Vol. 17 ›› Issue (03): 198-201.doi: 10.16138/j.1673-6087.2022.03.005
朱小霞
收稿日期:2022-01-12
出版日期:2022-05-30
发布日期:2022-08-09
Received:2022-01-12
Online:2022-05-30
Published:2022-08-09
中图分类号:
朱小霞. 浅谈痛风及高尿酸血症治疗热点问题[J]. 内科理论与实践, 2022, 17(03): 198-201.
| [1] |
Zhang M, Zhu XX, Wu J, et al. Prevalence of hyperuricemia among Chinese adults: findings from two nationally representative cross-sectional surveys in 2015-16 and 2018-19[J]. Front Immunol, 2022, 12: 791983.
doi: 10.3389/fimmu.2021.791983 URL |
| [2] |
Yu KH, Chen DY, Chen JH, et al. Management of gout and hyperuricemia: multidisciplinary consensus in Taiwan[J]. Int J Rheum Dis, 2018. 21(4): 772-787.
doi: 10.1111/1756-185X.13266 URL |
| [3] |
White WB, Saag KG, Becker MA, et al. Cardiovascular safety of febuxostat or allopurinol in patients with gout[J]. N Engl J Med, 2018, 378(13): 1200-1210.
doi: 10.1056/NEJMoa1710895 URL |
| [4] |
Zhang M, Solomon DH, Desai RJ, et al. Assessment of cardiovascular risk in older patients with gout initiating febuxostat versus allopurinol[J]. Circulation, 2018, 138(11): 1116-1126.
doi: 10.1161/CIRCULATIONAHA.118.033992 URL |
| [5] |
Chen CH, Chen CB, Chang CJ, et al. Hypersensitivity and cardiovascular risks related to allopurinol and febuxostat therapy in Asians[J]. Clin Pharmacol Ther, 2019, 106(2): 391-401.
doi: 10.1002/cpt.1377 URL |
| [6] |
Mackenzie IS, Ford I, Nuki G, et al. Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout(FAST)[J]. Lancet, 2020, 396(10264): 1745-1757.
doi: 10.1016/S0140-6736(20)32234-0 pmid: 33181081 |
| [7] |
Tardif JC, Kouz S, Waters DD, et al. Efficacy and safety of low-dose colchicine after myocardial infarction[J]. N Engl J Med, 2019, 381(26): 2497-2505.
doi: 10.1056/NEJMoa1912388 URL |
| [8] |
Shah B, Toprover M, Crittenden DB, et al. Colchicine use and incident coronary artery disease in male patients with gout[J]. Can J Cardiol, 2020, 36(11): 1722-1728.
doi: 10.1016/j.cjca.2020.05.026 URL |
| [9] |
Yamanaka H, Tamaki S, Ide Y, et al. Stepwise dose increase of febuxostat is comparable with colchicine prophylaxis for the prevention of gout flares during the initial phase of urate-lowering therapy: results from FORTUNE-1, a prospective, multicentre randomised study[J]. Ann Rheum Dis, 2018, 77(2): 270-276.
doi: 10.1136/annrheumdis-2017-211574 pmid: 29102957 |
| [10] |
Xue X, Liu Z, Li X, et al. The efficacy and safety of citrate mixture vs sodium bicarbonate on urine alkalization in Chinese primary gout patients with benzbromarone: a prospective, randomized controlled study[J]. Rheumatology (Oxford), 2021, 60(6): 2661-2671.
doi: 10.1093/rheumatology/keaa668 URL |
| [1] | 赵东宝. 风湿病继发骨质疏松症研究进展[J]. 内科理论与实践, 2022, 17(03): 181-185. |
| [2] | 祝洪明, 李啸扬, 普布旺堆, 巴顿, 方洁, 次仁央宗, 宗吉, 乐飞, 罗布卓玛. 红细胞单采术治疗高原红细胞增多症合并高尿酸血症[J]. 内科理论与实践, 2021, 16(04): 267-269. |
| [3] | 朱思奇, 吴梦雄, 秦乐, 董海鹏. 双能量CT评价痛风性关节炎骨髓水肿的可行性研究[J]. 诊断学理论与实践, 2019, 18(03): 340-343. |
| [4] | 刘磊, 吕小希, 于一云, 宣丹旦, 郑舒聪, 朱小霞, 张炯, 邹和建, 薛愉,. 痛风治疗药物新进展[J]. 内科理论与实践, 2016, 11(06): 401-404. |
| [5] | 赵东宝, 万伟, 徐霞,. 痛风诊断标准的演变及其影像学检查在临床中的应用[J]. 诊断学理论与实践, 2014, 13(03): 229-231. |
| [6] | 刘云庆, 张心菊, 关明,. 痛风和高尿酸血症的遗传学和药物基因组学介绍[J]. 诊断学理论与实践, 2013, 12(04): 396-400. |
| [7] | 邹和建, 姜林娣,. 2012年美国风湿病学会痛风治疗指南评析[J]. 内科理论与实践, 2012, 7(06): 458-460. |
| [8] | 林颖达, 朱小霞, 薛愉, 邹和建,. 痛风研究进展[J]. 内科理论与实践, 2011, 6(05): 379-386. |
| 阅读次数 | ||||||
|
全文 |
|
|||||
|
摘要 |
|
|||||
